LXRX - NASDAQ
Lexicon Pharmaceuticals, Inc.
$1.94
+2.4%Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
At a Glance
Live SnapshotLexicon Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Lexicon Pharmaceuticals, Inc. Income Statement
LXRX • NASDAQ
| Lexicon Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
49.8M | 31.1M | 1.2M | 139K | 298K | 24M | 322.1M | 63.2M | 90.3M | 83.3M | 130M | 22.9M | 2.2M | 1.1M | 1.8M | 4.9M | 10.7M | 32.3M | 50.1M | 72.8M | |
GROSS PROFIT | ||||||||||||||||||||
(274K) | (616K) | (59M) | (52.5M) | (55M) | (1.9M) | (3.2M) | (2.5M) | (1.9M) | (164M) | (95.2M) | (89.3M) | (89.7M) | (82.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
49.5M | 30.5M | -57.8M | -52.4M | -54.7M | 22.1M | 318.8M | 60.7M | 88.4M | -80.6M | 34.8M | -66.4M | -87.5M | -81.5M | 1.8M | 4.9M | 10.7M | 32.3M | 50.1M | 72.8M | |
OPERATING INCOME | ||||||||||||||||||||
(98.4M) | (227.6M) | (114M) | (48.4M) | (32.3M) | (69.9M) | (177.4M) | (164M) | (223M) | (221.2M) | (119M) | (108.7M) | (106.8M) | (99.6M) | (115.9M) | (100.6M) | (100.7M) | (128.9M) | (125.1M) | (128M) | |
(37.3M) | (131.9M) | (0.0) | (0.0) | (0.0) | (47.2M) | (56.8M) | (63.8M) | (66.2M) | (43M) | (23.8M) | (19.4M) | (17.1M) | (17M) | (17.4M) | (22.6M) | (19.4M) | (20.3M) | (20.7M) | (21.3M) | |
(61.1M) | (84.5M) | (58.9M) | (52.8M) | (55M) | (153.6M) | (91.9M) | (100.2M) | (156.8M) | (178.2M) | (95.2M) | (89.3M) | (89.7M) | (82.6M) | (91.8M) | (75.4M) | (81.2M) | (108.6M) | (104.3M) | (106.7M) | |
-48.9M | -197.1M | -171.8M | -100.8M | -87.1M | -47.8M | 141.4M | -103.3M | -136.7M | -137.2M | 1.5M | -100.4M | -102.4M | -108.4M | -114.1M | -95.7M | -90M | -96.5M | -75M | -55.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(8.3M) | (15.6M) | (13.1M) | (2.8M) | (802K) | (14.5M) | (20.7M) | (20.8M) | (7M) | (6.6M) | (6.7M) | (2.3M) | (2M) | (2.1M) | (2.5M) | (2.7M) | (3M) | (2.7M) | (2.8M) | (3.3M) | |
-1.4M | -3.3M | -5.4M | -1.2M | -668K | -11.8M | -17.3M | -17.3M | -5M | -4.3M | -6.2M | 2K | -1.8M | -1.8M | -2.3M | -2.2M | -2.1M | 3.1M | 4.5M | 400K | |
(0.0) | (11.2M) | (55.1M) | -4.4M | -22.7M | -131M | (28.6M) | (0.0) | (2M) | (2.3M) | (572K) | (2.3M) | (59K) | (105K) | (24.1M) | (2.7M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.4M | -3.3M | -5.4M | -1.2M | -668K | -10.8M | -17.3M | -17.3M | -5M | -4.3M | -6.2M | 2K | -1.8M | -1.8M | -2.1M | -6.1M | -3.5M | -349K | 3.7M | 801K | |
-50.3M | -200.4M | -177.1M | -101.9M | -87.8M | -58.6M | 124.1M | -120.5M | -141.7M | -141.4M | -4.7M | -100.4M | -104.1M | -110.2M | -116.2M | -101.8M | -93.4M | -96.9M | -71.2M | 54.4M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -6M | (0.0) | -12.7M | (4.5M) | (0.0) | -70K | -833K | (0.0) | (0.0) | -26K | -102K | (0.0) | -16.2M | -119K | |
-50.3M | -200.4M | -177.1M | -101.9M | -87.8M | -58.6M | 130.1M | -120.5M | -129.1M | -141.4M | -4.7M | -100.3M | -104.1M | -110.2M | -116.2M | -101.8M | -82.8M | -76.9M | -58.8M | -54.3M |
SEC Filings
LXRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 02, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your LXRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.